NovoCure Ltd - 8-K Filing

NovoCure reports Q3 2026 net revenues of $193.4 million and raises full-year 2026 revenue and Adjusted EBITDA guidance. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $NVCR

Read the full article at SEC EDGAR

Part of the story PG&E Corp - 8-K Filing (47 articles)

More Regulatory news